{"id":391,"date":"2026-01-26T14:44:16","date_gmt":"2026-01-26T13:44:16","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/26\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/"},"modified":"2026-02-03T11:01:14","modified_gmt":"2026-02-03T10:01:14","slug":"crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/","title":{"rendered":"Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”|auto|-1px|auto|false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

ClinicalTrials.gov ID:<\/strong> NCT05242471
Sponsor:<\/strong> Janssen Research & Development, LLC<\/p>\n

Official title:<\/strong>
Randomized, double-blind, active- and placebo-controlled, multicenter, phase 2b parallel-group study to evaluate the efficacy and safety of induction and maintenance therapy with guselkumab and golimumab in patients with moderately to severely active Crohn’s disease.<\/p>\n

Study overview:<\/strong>
The aim is to evaluate the efficacy of JNJ-78934804 at week 48 compared to guselkumab and golimumab.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ClinicalTrials.gov ID: NCT05242471Sponsor: Janssen Research & Development, LLC Official title:Randomized, double-blind, active- and placebo-controlled, multicenter, phase 2b parallel-group study to evaluate the efficacy and safety of induction and maintenance therapy with guselkumab and golimumab in patients with moderately to severely active Crohn’s disease. Study overview:The aim is to evaluate the efficacy of JNJ-78934804 at week […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-391","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"\nCrohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:44:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:01:14+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)\",\"datePublished\":\"2026-01-26T13:44:16+00:00\",\"dateModified\":\"2026-02-03T10:01:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/\"},\"wordCount\":289,\"articleSection\":[\"Active, recruitment completed\",\"For study partners\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/\",\"name\":\"Crohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\"},\"datePublished\":\"2026-01-26T13:44:16+00:00\",\"dateModified\":\"2026-02-03T10:01:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ced-study-center-karlshorst\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/author\\\/paulilauterbachnutzer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/","og_locale":"en_US","og_type":"article","og_title":"Crohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst","og_description":"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality […]","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-26T13:44:16+00:00","article_modified_time":"2026-02-03T10:01:14+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)","datePublished":"2026-01-26T13:44:16+00:00","dateModified":"2026-02-03T10:01:14+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/"},"wordCount":289,"articleSection":["Active, recruitment completed","For study partners"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/","name":"Crohn's disease: Combination study with guselkumab and golimumab in Crohn's disease (DUET-CD) - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-26T13:44:16+00:00","dateModified":"2026-02-03T10:01:14+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-combination-study-with-guselkumab-and-golimumab-in-crohns-disease-duet-cd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Crohn’s disease: Combination study with guselkumab and golimumab in Crohn’s disease (DUET-CD)"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=391"}],"version-history":[{"count":6,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/391\/revisions"}],"predecessor-version":[{"id":408,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/391\/revisions\/408"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}